In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Interview: Everything you need to know about becoming a clinical research associate
In this interview, Sara Brannon, Director of Quality and Training Development at ICON, discusses the approach to recruiting clinical research associates (CRAs) and how the industry is suffering from a global shortage due to a high demand for experienced associates.
-
Challenges of expanding CAR-T Cell Therapy into solid tumors
Learn more about the challenges associated with developing CAR-T therapies for solid tumors in this article.
© Huber, B.; Joeckel, T. Challenges of Expanding CAR-T Cell Therapy into Solid Tumors. BioPharm International 2023, 36 (5), 22–23,27
-
Clinical Data Management
In this article, Michael Phillips, discusses the ways in which machine learning can replace or augment traditional data review approaches while maintaining a risk-based, patient-centric approach and delivering higher quality outcomes with less human error.
-
The human condition
In this article, Patricia Murphy discusses how the industry needs to make rare disease clinical trials more human.
-
Making accessibility strategy part of your rare disease trial planning
In this article, Laura Iliescu, director of patient advocacy strategy at ICON Plc, discusses strategies to improve inclusion of people with disabilities in rare disease trials.
-
How decentralised and hybrid clinical trials can support subject recruitment and retention to support clinical trial success
Read Laney Preheim's article in International Pharmaceutical Industry.
-
Diverse teams drive great performance
Steve Cutler participated in the Business & Finance CEO Q&A in which he outlined his ambitions and priorities for ICON.
-
Transforming clinical trials in a rapidly shifting landscape
Dr Ute Berger, President, Development & Commercialisation Solutions outlines how ICON is transforming clinical trials in a rapidly shifting landscape in the Executive Interview in Drug Development & Delivery.
Copyright Drug Development & Delivery.
-
Data doesn't cut it - Payer engagement requires a humanistic approach
A drug’s ability to reach the market is essential; however, pharma manufacturers have struggled to meet the increased pressure to demonstrate the value of their drugs, particularly in therapeutic areas over-populated with treatment options. Data surrounding the success and efficacy of a drug are rarely sufficient to convince stakeholders that the drug is worth the investment. Payers have displayed a need for a more humanistic approach, and against this backdrop, manufacturers need to reconsider their engagement strategies.
-
Developing mRNA vaccine technology
In this article, Dinah Knotts, Vice President of Project Management at ICON, speaks about mRNA vaccine technology and what further opportunities it can offer in fighting infectious diseases.
